Maze Therapeutics (MAZE) Cash from Financing Activities (2024 - 2026)

Maze Therapeutics (MAZE) has 3 years of Cash from Financing Activities data on file, last reported at $42.4 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities fell 66.75% year-over-year to $42.4 million; the trailing twelve-month figure through Mar 2026 stood at $190.3 million (down 2.72% YoY), and the FY2025 full-year result was $275.3 million, up 196.55% from the prior year.
• Cash from Financing Activities advanced to $42.4 million in Q1 2026, from $3.6 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $143.8 million in Q3 2025 to a low of -$2.2 million in Q3 2024.
• A 3-year average of $45.6 million and a median of $24.6 million in 2024 frame the typical range for Cash from Financing Activities.
• Peak annual rise in Cash from Financing Activities reached 6786.37% in 2025, while the deepest fall reached 94.89% in 2025.
• Tracing MAZE's Cash from Financing Activities over 3 years: stood at $70.3 million in 2024, then sank by 94.89% to $3.6 million in 2025, then jumped by 1079.86% to $42.4 million in 2026.
• Business Quant data shows MAZE's Cash from Financing Activities at $42.4 million in Q1 2026, $3.6 million in Q4 2025, and $143.8 million in Q3 2025.